Mersana Therapeutics. has filed a patent for a combination therapy involving HER2-targeted STING agonist antibody-drug conjugates and HER2-targeted therapies or immunotherapies for cancer treatment. The therapy aims to enhance treatment efficacy through targeted delivery. GlobalData’s report on Mersana Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Mersana Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Mersana Therapeutics's grant share as of January 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
Combination therapy for cancer using her2-targeted treatments
A patent application (Publication Number: US20230398229A1) discloses a combination therapy for treating cancer, comprising a HER2-targeted STING agonist antibody-drug conjugate and either a HER2-targeted therapy or an immunotherapy. The conjugate specifically binds to the HER2 receptor, enhancing the efficacy of the therapy or immunotherapy. The HER2-targeted therapy can include antibodies like trastuzumab, pertuzumab, or margetuximab, while the immunotherapy can involve immune checkpoint inhibitors such as avelumab or pembrolizumab.
The method for treating cancer involves administering the combination therapy to a subject, with the option to target specific types of cancer like breast cancer, colorectal cancer, or non-small cell lung cancer. The therapy components can be administered simultaneously, sequentially, or in alternation, with the conjugate given before or after the therapy or immunotherapy. The patent also includes provisions for formulating the components together or separately, as well as a kit containing the combination therapy and administration instructions. This innovative approach aims to provide a comprehensive treatment option for various cancer types by leveraging the synergistic effects of the different components in the combination therapy.
To know more about GlobalData’s detailed insights on Mersana Therapeutics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
